SlideShare une entreprise Scribd logo
1  sur  79
Télécharger pour lire hors ligne
May 2, 2018
Serge Weinberg
Chairman of the Board of Directors
Introduction
Forward Looking Statements
3
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-
looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations,
services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that
the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and
statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that
could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and
when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding
labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's
ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related
pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic
conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017.
Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or
statements.
Agenda
4
2017 Financial Performance
Jérôme Contamine, Executive Vice-President,
Chief Financial Officer
Introduction & Governance
Serge Weinberg, Chairman of the Board of Directors
Compensation Policy
Patrick Kron, Chairman of the Compensation Committee
Progress in Research & Development
Elias Zerhouni, President, Global R&D
Strategic Outlook
Olivier Brandicourt, Chief Executive Officer
Reports by Statutory Auditors at the
Combined General Meeting
PricewaterhouseCoopers Audit
ERNST & YOUNG et Autres
Questions & Answers
Vote on the Resolutions
Serge Weinberg
Chairman of the Board of Directors
Governance
An Independent, Experienced and Diversified
Board of Directors
6
(1) Numbers not taking into account directors representing employees, pursuant to the recommendations of the AFEP-MEDEF Corporate Governance Code
(2) Percentage not taking into account directors representing employees, pursuant to the relevant regulation
• Board of Directors composed of 16 directors
• Widely independent (11 out of 14(1)) and gender sensitive (43%(2))
• International (6 non-French directors, i.e. 38%)
• 2 directors representing employees
• Further implementation of roadmap with
a controlled and progressive renewal
• More scientific and pharmaceutical expertise
• Development of competences in the digital area
• Preservation of key competences
• Restricted number of directorships allowing an enhanced
participation and dedication
Renewal of the terms of:
• Olivier Brandicourt
• Christian Mulliez
• Patrick Kron
Appointment of:
• Emmanuel Babeau
A Dedicated and Active Board of Directors
In 2017
• A sustained level of activity: 9 meetings
• Activities related to:
• financial statements and financial matters
• compensation matters
• appointment and governance matters
• Review of significant proposed alliances,
acquisitions and strategic opportunities
• Review of key businesses
• Evaluation of the activities of the Board and its
Committees
• 3 executive sessions
7
High directors’
attendance rate
> 95 %
Four Specialized Committees
1. Audit Committee
• Chaired by Robert Castaigne(1)
• 3 financial experts
• 3 independent members out of 4
• 7 meetings in 2017
• Review of the annual, half-year and quarterly
financial results
• Review of the main risks that may affect the results
• Review of the draft financial resolutions
• Update on the implementation of IFRS 15
and IFRS 9 accounting standards
8
1 1. Compensation Committee
• Chaired by Patrick Kron
• 3 independent members out of 4
• 3 meetings in 2017
• Review of the fixed and variable compensation of the
CEO, the Chairman of the Board, and the members
of the Executive Committee
• Determination of the amount of directors’ attendance
fees
• Update on changes in « say on pay » requirements
• Launch of a new employee share-ownership plan
2
Attendance rate: 93% Attendance rate: 100%
(1) Following this General Meeting, the Audit Committee will be chaired by Fabienne Lecorvaisier
Four Specialized Committees (cont’d)
1. Appointments and Governance
Committee
• Chaired by Serge Weinberg
• 3 independent members out of 3
• 3 meetings in 2017
• Succession planning
• Follow-up of the discussions held with main
shareholders and proxy advisors on governance
matters
• Evaluation of the activities of the Board and its
Committees
• Changes in the Board’s composition
9
3 1. Strategic Committee
• Chaired by Serge Weinberg
• 2 independent members out of 4
• 10 meetings in 2017
• Review of external growth opportunities
• Review of the strategy
• Global environment
• Research and development
• Long range financials
4
Attendance rate: 100% Attendance rate: 100%
A Fifth Specialized Committee in 2018
1. Scientific Committee
• Decision of the Board of Directors on March 6, 2018,
upon recommendation of the Appointments and
Governance Committee
• Scientific Committee in charge of assisting the Board
on the strategic orientations in the field of R&D
• Thomas Südhof appointed Chairman of the Committee
10
5
Creation
in 2018
Sanofi Share Performance vs. Pharma Company Peers since
January 2018
11
Stock Performance in local currencies
Source: Bloomberg, April 27, 2018
Local currencies: € for SAN & Bayer; US $ for LLY, PFE, MRCK, ABBV, BMY, JnJ, AZ & Novartis; DKK for Novo; CHF for Roche; £ for GSK
10.8%
5.7%
2.2%2.1%
-0.7%
-2.1%
-5.6%
-7.3%-7.9%-8.2%-9.3%
-11.3%
-13.6%
-14.7%
ADR
Dividend: A Crucial Element of the Return to Shareholders
• 2017 dividend proposed by the Board of Directors: €3.03 per share(1)
• 24th consecutive year of dividend increase
12(1) Submitted to the vote of this General Meeting
Evolution of Dividend
€2.20 €2.40 €2.50 €2.65 €2.77 €2.80 €2.85 €2.93 €2.96 €3.03
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
An International and Diversified Shareholder Base
13Source: NASDAQ Corporate Solutions, December 31, 2017
United States
France
Institutional
Investors
76.7%
UK
Other EU countries
Asia
Germany
Switzerland
Canada
Rest of the world
L’Oréal
Individual Shareholders
Employees
Miscellaneous
1,254,019,904
shares
1.5%
9.4%
5.9%
6.5%
1.6%
14.5%
29.1%
2.2%
3.3%
1.6%
3.3%
6.6%
14.6%
7.4%
Strenghten Employee Share Ownership
Sanofi wants to
strenghen its employee
share ownership
• 22nd resolution voted by the
AGM of May 10, 2017
• For an implementation in
June 2018
• In more than 70 countries
14
3 initiatives since 2013
Action 2013 Action 2016 Action 2017
>1.6 million
shares
subscribed
>1.7 million
shares
subscribed
>1.5 million
shares
subscribed
Patrick Kron
Chairman of the Compensation Committee
Compensation Policy
Compensation Policy for the Chairman of the Board
16
• Stable annual fixed gross
compensation
• No attendance fees
• No annual variable compensation
• No equity compensation
• No compensation payable upon
termination of office
• No pension entitlement
• No exceptional compensation
Compensation Elements of Serge Weinberg in 2017
17
Amounts Comments
Fixed compensation €700,000
Fixed compensation unchanged since
his appointment on May 17, 2010
€8,353 Company car
Total €708,353
Compensation Policy for the Chief Executive Officer
18
• Annual fixed compensation
• Annual variable compensation
• Equity compensation
• Options to subscribe for shares
• Performance shares
• No Director’s attendance fees
• No exceptional compensation
• Compensation on leaving office
• Termination benefit
• Top-up pension benefit subject to
fulfillment of a performance condition
(voluntary implementation of the Macron law as of
January 2017)
• Non-compete undertaking
Compensation Elements of Olivier Brandicourt in 2017
19
(1) In accordance with article L. 225-100 of the French commercial code, payment of annual variable compensation in respect of the year ended on December 31, 2017
is contingent on favorable vote at this General Meeting
Amounts Comments
Fixed compensation €1,200,000
Same compensation since his appointment in
2015
Variable compensation €1,792,800(1)
From 0% to 250% of the target fixed
compensation to 150% of the fixed compensation
Achieved rate: 149.4% of fixed compensation
Options
220,000 options to
subscribe for shares
Exercise price: €88.97
Performance shares
50,000
performance shares
Benefits in kind
€318
Social benefit in relation to social contribution
payment made by Sanofi on CEO’s behalf
Variable Compensation of Olivier Brandicourt in 2017
20
• 40% based on financial indicators
• 60% based on specific individual objectives
• External growth (14%)
• Excellence of product launches (10%)
• Operational transformation (12%)
• Organization and staff relations (12%)
• New product pipeline (12%)
• Quantitative criteria account for 76% of the overall
annual gross variable compensation objectives
Attainment
99.6% of the
150% target,
i.e. 149.4% of the
fixed compensation
Equity Compensation of Olivier Brandicourt in 2017
21
• Performance conditions measured over 3 years
• 3 performance criteria
• Business Net Income (50%)
• Return On Assets or ROA (30%)
• Total Shareholder Return or TSR (20%)
• 220,000 options to
subscribe for shares
• 50,000 performance
shares
2017 Grant Plan Conditions
2015 Plan
• Allocation rate
of 81.12%
• Definitive acquisition
in June 2019
• Performance conditions measured over 3 years (2015-2017)
• 3 performance criteria
• Business Net Income (50%) – 102.2%
• Return On Assets or ROA (30%) – 100%
• Total Shareholder Return or TSR (20%) – 0%
Plan Conditions
Olivier Brandicourt
Chief Executive Officer
Strategic Outlook
Sanofi, a Health Journey Partner
23
General Meeting 2018
For 3 Years: Strategic Transformation for Better Healthcare
and Continued Value Creation
25
An unprecedented effort in
Research & Development
1
2
3
4 Impact of digital opportunities
A new operational model
Refocusing on our strenghs
A Robust R&D Pipeline in 6 Therapeutic Areas
• €5.5bn invested in R&D in 2017
• 15.6% of company sales
• 74 projects in development
• Immunology
• Multiple Sclerosis & Neurology
• Oncology
• Rare Diseases & Rare Blood Disorders
• Diabetes & Cardiovascular
• Vaccines
26
3737
Studies for
additional
indications
NMEs &
Vaccines in
developement
28Molecules & vaccines
in late stage
development
1 An unprecedented effort in Research & Development
Dupixent® Launched in Atopic Dermatitis
A Product with Multiple Potential Indications
• Moderate-to-Severe Atopic Dermatitis
• Strong launch in the U.S.
• Ongoing or planned launches in 20 countries
in the coming months
• Moderate-to-Severe Asthma
• Regulatory submissions in the U.S. and Europe
• Significant commercial potential in multiple
diseases(1)
• Nasal Polyposis, Eosinophilic Esophagitis, Chronic
Obstructive Pulmonary Disease, Allergies…
27(1) If approved in indications by relevant Health Authority
1 An unprecedented effort in Research & Development
Pictures of a patient from a Phase 3 clinical trial before and after
treatment with dupilumab. Results may vary
2017 Sales:
€219m
Two Promising Products in Oncology
28
cemiplimab isatuximab
• PD-1 inhibitor monoclonal
antibody
• Being evaluated by European
and U.S. health authorities in
Cutaneous Squamous Cell
Carcinoma
• Phase 3 studies ongoing in
other cancers
Cemiplimab is partenered with Regeneron
Cemiplimab and isatuximab are currently investigational agents and have not been evaluated by any regulatory authority
• Anti-CD38 monoclonal
antibody
• Pivotal studies in Multiple
Myeloma (bone marrow
cancer) ongoing;
submission planned in 2018
1 An unprecedented effort in Research & Development
Praluent® Significantly Reduces Risk of Cardiovascular
Events in High-Risk Patients
29
Praluent® (alirocumab) is developed in collaboration with Regeneron
For more information: consult the press release from March 10, 2018
(1) HR=0.85, IC : 0.78-0.93, p=0.0003
(2) HR=0.85; IC: 0.73-0.98, nominal p value = 0.026
Approved in more
than 60 countries
Focus on patients
with the greatest
health risk
Praluent® significantly reduced the
risk of major adverse cardiovascular
events(1)
Associated with a reduction in
all-cause mortality(2)
A more pronounced effect
observed in patients with baseline
LDL-C levels ≥ 100 mg/dL



1 An unprecedented effort in Research & Development
For 3 Years: Strategic Transformation for Better Healthcare
and Continued Value Creation
30
An unprecedented effort in
Research & Development
1
2
3
4 Impact of digital opportunities
A new operational model
Refocusing on our strenghs
Consolidating our Leadership in Rare Diseases
31
2 Refocusing on our strengths
Restructuring of the
alliance with Alnylam
• Global rights obtained on
fitusiran, currently in
Phase 3 in hemophilia
1
Building a center of expertise
in rare blood disorders
Three complementary moves
Bioverativ: a Leading Hemophilia Portfolio, a New Platform in
Other Rare Blood Disorders
32
U.S. biotechnology company
• 2017 Revenues: $1,168m, +31.7%
Leadership position in the large hemophilia market
• Two marketed products
R&D programs
• Cold agglutinin disease, hemophilia and other rare blood
disorders
(1) (2)
(1) Treatment of Hemophilia A
(2) Treatment of Hemophilia B
2 Refocusing on our strenghs
2
Belgian biotechnology company
• An innovative Nanobody® platform which strengthens
Sanofi’s multi-targeting R&D strategy
Ablynx: Provides a Leading Technology Platform and
Strengthens R&D Pipeline(1)
33
Expanding rare blood disorders franchise(2)
• Caplacizumab: submitted in Europe for the treatment of
Acquired Thrombotic Thrombocytopenic Purpura
Complementary R&D programs
• Hematology, inflammatory diseases, immuno-oncology,
respiratory diseases
(1) Subject to the completion of the acquisition
(2) Linked to Bioverativ’s acquisition
2 Refocusing on our strenghs
3
Flu Vaccines: Protein Sciences Broadens our Portfolio with
Flublok®
34
65 year
old
50 year
old
6 month
old
Change standard of care
Age-related product differentiation
Flublok(1)
Fluzone HD QIVFluzone HD TIV
Better efficacy
Fluzone QIV
VaxiGrip QIV
Fluzone TIV
VaxiGrip TIV
HD= High-Dose; TIV= trivalent; QIV= quadrivalent
(1) The only FDA approved recombinant protein-based influenza vaccine approved for all adults 18 and older
Better efficacy
2 Refocusing on our strenghs
For 3 Years: Strategic Transformation for Better Healthcare
and Continued Value Creation
35
An unprecedented effort in
Research & Development
1
2
3
4 Impact of digital opportunities
A new operational model
Refocusing on our strenghs
An Organization Based on Five Global Business Units (GBUs)
36
Sanofi Genzyme
Specialty Care
Sanofi Pasteur
Vaccines
Diabetes &
Cardiovascular
Consumer
Healthcare
General Medicines &
Emerging Markets
5
GBUs
3 A new operational model
For 3 Years: Strategic Transformation for Better Healthcare
and Continued Value Creation
37
An unprecedented effort in
Research & Development
1
2
3
4 Impact of digital opportunities
A new operational model
Refocusing on our strenghs
Digitalization Offers Enormous Potential
38
4
• Accelerating research
• Better diabetes management,
beyond medicines
• Better interaction with patients,
physicians and payers
• Digitalization of the industrial tool
Impact of digital opportunities
A diversified and strong model based on three categories of
activity
39
High scientific
content
Strong added value
Diabetes
and cardiovascular
disease
Predictable
and
profitable growth
1 2 3
Sanofi Genzyme – Specialty Care
Success of the New Immunology Franchise
Immunology
• Successful launch of Dupixent®
• Kevzara® launch progressing well
Multiple Sclerosis
• Strong, growing franchise
Rare Diseases
• Bioverativ acquisition and Ablynx
planned acquisition strenghten
leadership position(1)
Oncology
• Significant expansion of
development pipeline
40
Global Specialty Care
Franchise Sales
€6,678m
19% of company sales
+14.5%
at CER
Immunology
Multiple Sclerosis
Rare Diseases
Oncology
2017
CER = Constant Exchange Rates
(1) Subject to the completion of the Ablynx acquisition
Sanofi Pasteur – Vaccines
A Global Leader in a Growing Market
41
Global Vaccines
Franchise Sales
€5,101m
14.6% of company sales
Pediatric Combinations
Influenza Vaccines
Meningitis/Pneumo
Adult Boosters
Travel/Endemic
Other
+14.5%
at CER
2017
Leading vaccines in 5 areas:
• Influenza
• Pediatric Combinations
• Meningitis
• Adult Boosters
• Travelers and other vaccines for
endemic countries
A strenghtened product
portfolio with the acquisition
of Protein Sciences
CER = Constant Exchange Rates
Diabetes and Cardiovascular Diseases
42
Diabetes Franchise
• Global sales down 11.1%
at CER in 2017
• Decrease in U.S. sales
partly offset by performance
in Emerging Markets
• Success of Toujeo® in 2017:
sales up 27% to €816m
Cardiovascular Franchise
• Praluent®: positive results of
ODYSSEY OUTCOMES
Global DCV Franchise Sales
€6,905m
19.7% of company sales
United States
Europe
Emerging
Markets
Rest of the
World
-20.2%
+0.1%
+11.6%
-0.6%
2017
All growth rates are expressed at Constant Exchange Rates (CER)
Sanofi is One of the Top 3 Players in Consumer Healthcare(1)
43
Integration of Boehringher Ingelheim
CHC business completed
Global CHC
Franchise Sales
€4,832m
13.8% of company sales
+46.3%
at CER
Allergies,
Cough & Cold
Pain
Nutritionals
Digestive
Other
2017
CER = Constant Exchange Rates
(1) Source: Nicholas Hall & Company FY 2017
General Medicines & Emerging Markets: Leading Position in
Emerging Countries Due to an Adapted Product Portfolio
44
(1) World excluding U.S., Canada, Europe, Japan, South Korea, Australia, New Zealand and Puerto Rico
(2) Market share (without Vaccines), IMS MIDAS | FY 2017
(3) At Constant Exchange Rates and Constant Structure
Established Products
• Account for nearly
one third of company sales
Emerging Markets(1)
• Sanofi ranks #1(2)
• 2017 sales: €10,258m, +6.0%(3)
• Supported by strong sales growth in China:
€2.2bn, +15.1%(3)
2017 GEM Business Unit Sales
€14,048m
40% of company sales
Progress in Protecting the Environment
• Water saving
• Objective: reduce water
consumption between 2010
and 2020 by 25 %
• Carbon footprint
• Objective: reduce greenhouse gas
emissions by 50 % in 2025
45
- 22%
water
consumption
at the end
of 2017
- 23%
greenhouse gas
emissions
since 2010
Access to Healthcare for Those Most in Need
in Emerging Countries
• Commitment against infectious
diseases
• Malaria: >450 million treatments provided
in 10 years
• Tuberculosis
• Poliomyelitis: world leader in polio vaccine
• Fight against tropical neglected
diseases
• Sleeping sickness
• In 15 years: reduction from 30,000 to 2,000 cases
• Fexinidazole, developed with DNDi, would be the
first all-oral treatment
Polio
Number of
cases down
99%
in 30 years
DNDi (Drugs for Neglected Diseases initiative): a not-for-profit research and development organization working to deliver new treatments for neglected diseases 46
Take Action for Disadvantaged Children and Educate them
About Health
• Sanofi Espoir Foundation –
My Child Matters
• For 12 years, enabling children with cancer
in low-income countries to benefit
from better care
• Kids
• Preventing diabetes in children at school
and encourage healthy lifestyles
• Program launched in Brazil, the United Arab
Emirates, Egypt, Japan, India, Pakistan and
Poland
55
projects in
42
countries
Actions in
175 schools,
>60,000
children
47
In France: Promoting Access to Healthcare for Those in Need
• Women in vulnerable situations
• Pregnancy monitoring at the
Maison des femmes de St Denis
• Those who live on the street
• Partnerships with: Samu social, Croix Rouge
Française, Emmaüs, Médecins du Monde
• Migrants
• A new program prepared
by Sanofi Espoir Foundation
48
Elias Zerhouni
Président, Global R&D
Progress in R&D
Key Achievements in R&D in 2017
50
(1) In collaboration with Regeneron
(2) In collaboration with Hanmi
(3) In collaboration with Lexicon
Pivotal study starts
Regulatory
submissions
Product
approvals
• Dupixent®(1) in Atopic Dermatitis in adult patients
• Kevzara®(1) in Rheumatoid Arthritis
• Suliqua® in Diabetes (Europe)
• Dupixent®(1) in Asthma in adult patients (U.S.)
• VaxiGrip® QIV IM in 6-35 month-olds (EU)
• Dupixent®(1) in Asthma in patients aged 6-11 year-old
• Dupixent®(1) in Atopic Dermatitis in patients 6-11 years-old,
12-17 years-old, 6 month-5 years-old
• Dupilumab(1) in Nasal Polyposis
• Efpeglenatide(2) in type 2 Diabetes
• Sotagliflozin(3) in combination therapies in type 2 Diabetes
• Isatuximab in Multiple Myeloma and other cancers
• Cemiplimab(1) in Non-small Cell Lung Cancer,
Basal Cell Carcinoma and Cervical Cancer
• Fluzone ® QIV HD
Key R&D Milestones in 2018
51
Q1 Q2 Q3 Q4
Potential
submissions
Cemiplimab(1) in Cutaneous Squamous Cell Carcinoma 
Sotagliflozin(2) in Type 1 Diabetes 
Dupilumab(1) in Asthma in adolescents/adults (EU) 
Praluent®(1) ODYSSEY OUTCOMES label update
Dupilumab(1) in Atopic Dermatitis in adolescents
Isatuximab in Multiple Myeloma in combination with PomDex (U.S.)
Expected
pivotal trial
read-outs
Praluent(1) ODYSSEY OUTCOMES 
Cemiplimab(1) in Basal Cell Carcinoma
Dupilumab(1) in Nasal Polyps
Expected start
of pivotal
studies
Mavacamten(3) in Obstructive Hypertrophic Cardiomyopathy
Fitusiran in Hemophilia A & B as prophylactic treatment 
Isatuximab in 1st line Multiple Myeloma in Stem Cell Transplant eligible patients
Venglustat in Autosomal Dominant Polycystic Kidney Disease
Sotagliflozin(2) in Worsening Heart Failure in Diabetes patients
Dupilumab(1) in Eosinophilic Esophagitis
Dupilumab(1) in Chronic Obstructive Pulmonary Disease
Alemtuzumab in Primary Progressive Multiple Sclerosis
(1) In collaboration with Regeneron
(2) In collaboration with Lexicon
(3) In collaboration with Myokardia
New R&D Model Based on Three Strategical Transformations
52
Mode
of action
biologicsTherapeutic
Modalities
small molecules
mono-targeting
Technology
Platforms
licensing proprietary
multi-targeting
Sanofi Focuses on Leading Technology Platforms
Addressing Multiple Disease Targets with Single Complex Molecules
siRNA
Conjugates
BioNTech
mRNA Mixture
PRR Antibody
Conjugates
Trigonal
Peptides
53
Multispecific
Antibodies
(bi- & tri-specific)
Ablynx
Nanobodies
PRR: Pattern Recognition Receptor
CH2
CH3
VHHVHH
Acquisition of Ablynx
internalizes platform for
Nanobodies®, a novel
class of next-generation
biologics
Build New Foundations for Growth
54
Multiple
Sclerosis
Cardiovascular
Immunology
Oncology
Hematology
2011 2012 2013 2014 2015 2016 2017 2018 2019
Diabetes
Dupilumab – A Pipeline in a Product
Being Developed in Multiple Indications
55
dupilumab
Atopic Dermatitis Asthma Nasal Polyposis
Eosinophilic
Esophagitis
• Breakthrough therapy in
moderate-to-severe AD
• First-in-class biologic
treatment
• Efficacy in
3 pivotal trials
• Largest Phase 3
program of a biologic
therapy in asthma
• Positive Proof of
Concept data
• No currently approved
biologic
• Phase 3 expected to
start in Q4 2018
• Positive Proof of
Concept data
• No currently approved
biologic
• Phase 3 fully enrolled
Dupilumab is developed in collaboration with Regeneron
ODYSSEY OUTCOMES Provides Strong Clinical Evidence of
Patient Benefit from Long-Term Therapy with Praluent®(1)
56
Praluent® is developed in collaboration with Regeneron
ACS = acute coronary syndrome; LDL-C = low-density lipoprotein cholesterol
(1) In addition to maximally tolerated statin therapy
(2) HR= 0.85, CI: 0.78-0.93, p=0.0003
(3) HR= 0.85; CI: 0.73-0.98; nominal p value = 0.026
(4) HR= 0.76, CI: 0.65-0.87 et HR=0.71, CI: 0.56-0.90 respectively
Long-term trial
~19,000 patients
Patient Impact
• Greatest clinical benefit shown
in high risk post-ACS patients
• In highest risk patients with
LDL-C ≥100mg/dL, Praluent® was
associated with a 24% reduction
of major adverse cardiovascular
events and 29% reduction in
all-cause death(4)
Positive Results
• Significant reduction in major
adverse cardiac events of 15%(2)
• Associated with 15% reduction in
all-cause mortality(3)
• Safety profile consistent with
previous findings
Screening
Cemiplimab: Promising Results in Treatment of Cutaneous
Squamous Cell Carcinoma
• One of the most common cancers
globally with significant unmet needs
• 200K to 400K new cases/year in the U.S.(1)
• Severe morbidity and mortality with recurrence
• ~3,900 – 8,800 deaths/year in the U.S.(1)
• Pivotal studies in other indications
• Non-Small Cell Lung Cancer
• Basal Cell Carcinoma
• Cervical Cancer
57
Results after 6
weeks treatment
with cemiplimab
Cutaneous Squamous Cell Carcinoma - Results from Phase 2 Pivotal Study
(1) Karia PS and al. J Am Acad Dermatol. 2013;68:957–66
Isatuximab: a Significant Opportunity in Large and Growing
Multiple Myeloma Market
• Worldwide Multiple Myeloma market expected to reach $29bn in 2022(1)
• Double/triple branded combination use
• New options with prolonged progression free
survival benefit
• Globally ~114k new cases diagnosed annually
• Anti-CD38 class rapidly becoming
standard of care
• Combinability without increased toxicity
• Unprecedented progression free survival
prolongation
• Proof of concept studies to evaluate combination use of isatuximab
in 9 other cancers
58
$14bn
$29bn
2017 2022e
Anti-CD38
IMiDs
PI’s
Other
Isatuximab is an investigational agent and has not been evaluated by any regulatory authority
IMiD= immunomodulatory agent; PI= proteasome inhibitor
(1) EvaluatePharma® October 2017
A continuous innovation flow(1)
59
fitusiran(7)
siRNA inhibitor
Hemophilia A/B - U.S./EU
2022 and beyond2018 2019 2020
(1) Excluding Phase 1 - Data related to all studies published on clinicaltrials.gov
(2) Also known as SAR439684 and REGN2810
(3) Also known as SAR231893
(4) Submission strategy for the U.S. under evaluation
(5) Submission for the U.S. expected in 2020
(6) Acid Sphingomyelinase Deficiency
(7) Following the Alnylam/Sanofi strategic restructuring of the RNAi therapeutics rare
disease alliance announced in January 2018, Sanofi now has global rights on fitusiran
(8) Currently operating as separate entities. Reported dates are based on prior Bioverativ
disclosure of study completion date
(9) Gaucher Related Parkinson’s Disease
(10)Also known as MEDI8897
(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some
of these products
NewmolecularentitiesAdditionalIndications
Dupixent®(**)
Anti-IL4Rα mAb
AD 6 months - 5 years old
U.S./EU
Tuberculosis
Recombinant subunit vaccine
GZ389988
TRKA antagonist
Osteoarthritis - U.S./EU
SAR425899
GLP-1/GCG dual agonist
Obesity/Overweight in T2D
U.S./EU
isatuximab
anti-CD38 mAb
3L RRMM (ICARIA) - U.S.
cemiplimab(2)(**)
PD-1 inhibitor mAb
Advanced CSCC - U.S./EU
HIV
Viral vector prime & rgp120
boost vaccine
SAR156597
IL4/IL13 bi-specific mAb
Systemic Scleroderma - U.S./EU
efpeglenatide(**)
Long acting GLP1-R agonist
Type 2 Diabetes - U.S./EU
cemiplimab(2)(**)
PD-1 inhibitor mAb
1L NSCLC - U.S./EU
cemiplimab(2)(**)
PD-1 inhibitor mAb
2L Cervical Cancer - U.S./EU
Men Quad TT
Adv. generation meningococcal
U.S. & EU – 10 Yrs +
SP0232 mAbs(10)(**)
Respiratory syncytial virus
U.S.
SAR422459
ABCA4 gene therapy
Stargardt Disease -- U.S./EU
avalglucosidase alfa
Neo GAA
Pompe Disease - U.S./EU
SAR407899
rho kinase
Microvascular Angina - U.S./EU
dupilumab(3)(**)
Anti-IL4Ra mAb
Nasal Polyposis Adult - U.S./EU
sarilumab(**)
Anti-IL6R mAb
Polyarticular Juvenile
Idiopathic Arthritis - U.S./EU
Dupixent®(3)(**)
Anti-IL4Ra mAb
AD 12 – 17 years old - U.S./EU
Rabies VRVg
Purified vero rabies vaccine
venglustat
Oral GCS inhibitor
Fabry Disease - U.S./EU
cemiplimab(2)(**)
PD-1 inhibitor mAb
Advanced BCC - U.S./EU
Praluent®(**)
Anti-PCSK9 mAb
CV events reduction - U.S./EU
Shan 6
DTP-HepB-Polio-Hib
Pediatric hexavalent vaccine
dupilumab(3)(**)
Anti-IL4Rα mAb
Asthma 6 - 11 years old
U.S./EU
venglustat
Oral GCS inhibitor
Gaucher Disease Type 3
U.S./EU
Dupixent®(3)(**)
Anti-IL4Ra mAb
AD 6 - 11 years old - U.S./EU
dupilumab(3)(**)
Anti-IL4Ra mAb
Eosinophilic Esophagitis
U.S./EU
Fluzone® QIV HD
Quadrivalent inactivated
Influenza vaccine - High dose
dupilumab(3)(**)
Anti-IL4Ra mAb
Asthma adults & adolesc. - EU
Adacel+
Tdap booster
sotagliflozin(**)n
Oral SGLT-1&2 inhibitor
Type 2 Diabetes – EU(5)
olipudase alfa
rhASM
ASD(6) - U.S./EU
sotagliflozin(**)n
Oral SGLT-1&2 inhibitor
Type 1 Diabetes - U.S./EU
Combination
ferroquine / OZ439(**)
Antimalarial - U.S./EU
venglustat
Oral GCS inhibitor
GrPD(9) - U.S./EU
Aubagio®
teriflunomide
Relapsing MS – Ped. - U.S./EU
sarilumab(**)
Anti-IL6R mAb
Systemic Juvenile Arthritis
U.S./EU
SAR341402
Rapid acting insulin
Type 1/2 Diabetes - EU(4)
Pediatric pentavalent
vaccine
DTP-Polio-Hib (Japan)
isatuximab
Anti-CD38 mAb (IMROZ)
1L Newly Diagnosed MM
U.S./EU
isatuximab
Anti-CD38 mAb
1-3L RRMM (IKEMA) - U.S./EU
2021
sotagliflozin(**)
SGLT 1/2 inhibitor
Worsening Heart Failure in
Diabetes - U.S./EU
Infectious DiseasesRare Diseases
Immuno-inflammation Diabetes
MS, Neuro, Gene therapy
Vaccines
Oncology Cardiovascular & metabolism
Rare Blood Disorders
SAR440340(**)
Anti-IL33 mAb
Asthma - U.S./EU
BIVV009(8)
Anti Complement C1s mAb
Cold Agglutinin Disease
SAR566658
Maytansin-loaded anti-CA6
mAb
Triple Negative Breast Cancer
Jérôme Contamine
Executive Vice-President, Chief Financial Officer
2017 Financial Performance
2017 Business EPS in-Line with Expectations
Sales
61
CER = Constant Exchange Rates
CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others
Business EPS
2017
€35,055m
2016
€33,821m
+0.5%
at CER/CS
€5.68
20172016
€5.54
-0.4%
at CER/CS
2017: A Year of Transition Supported by Solid Growth Drivers
62
Growth
at CER% of Sales
Growth
at CER/CS
CER = Constant Exchange Rates
CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others
19.1%
14.6%
19.7%
Specialty Medicines
Vaccines
Diabetes & Cardiovascular
€6,678M
€5,101M
€6,905M
€1,778M
+14.5%
+14.5%
-9.6%
71.6% Pharmaceuticals €25,122M
5.1%
27.7% Established Rx Products
Others
€9,761M -3.4%
-3.3%
+14.6%
+8.3%
-9.6%
-3.8%
-3.1%
13.8% Consumer Healthcare €4,832M +46.3% +2.1%
-1.2% -1.3%
33.8% 27.2%
29.3%9.7%
A Balanced Geographic Breakdown of Sales
63
United States
€11,855m
-3.5%
Europe(1)
€9,525m
+0.7%
Emerging
Markets(2)
€10,258m
+6.0%
Rest of World(3)
€3,417m
-1.5%
All growth at CER (constant exchange rates) / CS (constant structure), adjusted for BI CHC
business, termination of SPMSD and others
(1) Western Europe & Eastern Europe (excluding Eurasia)
(2) World excluding U.S., Canada, Europe, Japan, South Korea, Australia,
New Zealand and Puerto Rico
(3) Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico
Strong sales growth in China:
€2,2bn, +15.1%
Sanofi Met 2017 Financial Performance Objectives
64
FY 2017 ResultsObjectives
Gross margin 70.6%70-71% at CER
OpEx growth rate at CER +2.0%
At similar rate
as in 2016(1)
Tax rate 23.5%24-25%
Business EPS guidance at CER -0.4%Broadly stable
Dividend growth +2.4%Progressive





CER = Constant Exchange Rates
(1) OpEx growth rate of 2.5% at CER in 2016
Business Operating Income Up 3% at CER in 2017
65
€m 2017 2016 %Change
(reported €)
% Change
(CER)
% Change
(CER/CS)
Sales 35,055 33,821 +3.6% +5.6% +0.5%
Other revenues 1,149 887 +29.5% +32.9% +36.6%
Gross profit 24,759 24,006 +3.1% +5.3% +0.4%
R&D expenses (5,472) (5,172) +5.8% +7.0% +5.0%
SG&A expenses (10,058) (9,486) +6.0% +7.8% +0.4%
Business operating income 9,343 9,285 +0.6% +3.0% -1.1%
Effective tax rate 23.5% 23.3% - - -
Business net income excluding Animal Health 6,964 6,832 +1.9% +4.2% -
Business net income of Animal Health - 476 -100.0% -100.0% -
Business net income 6,964 7,308 -4.7% -2.6%
CER = Constant Exchange Rates
CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others
Continued Investment in R&D and Strict Cost Management
Gross Margin
66
R&D Expenses SG&A Expenses
201720162017201620172016
15.6%
of sales
28.7%
of sales
€10,058m
€5,472m
€5,172m
€9,486m
28.0%
of sales
15.3%
of sales
70.6%
71.0% +5.0%
+0.4%
All growth rates at CER = Constant Exchange Rates / CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others
Net Income Benefited From Gain on the Disposal of the
Animal Health Business
67(1) In 2016: other elements SPMSD: €52m, Impairment loss on Alnylam investment: €457m
€m 2017 2016 % Change
(reported €)
Business net income 6,964 7,308 (4.7%)
Amortization of intangible assets (1,866) (1,692)
Impairment of intangible assets (293) (192)
Fair value remeasurement of contingent consideration liabilities (159) (135)
Expenses arising from the impact of acquisitions on inventories (166) -
Restructuring costs and similar items (731) (879)
Other gains and losses, and litigation (215) 211
Tax effect of items listed above 1,126 841
Other tax items (742) (113)
Associates and non-controlling interests (127) 31
Animal Health items 4,643 (162)
Others(1) - (509)
Net income attributable to equity holders of Sanofi 8,434 4,709 79.1%
Strong Balance Sheet on December 31, 2017
68
ASSETS
LIABILITIES
& EQUITY
Net Debt (A-B)
Intangible assets
Other non-current assets
WCR(1)
Net cash (B)
Equity attributable
Provisions and other non-current liabilities
Financial debt (A)(2)
58.3
11.8
(1) Working Capital Requirement
(2) Including interest rate and currency derivatives used to hedge debt
5.2
+2.2
-0.3
+0.2
+0.0
+0.6
-0.7
-3.0
53.4
20.1
1.8
10.3
15.5
-3.0
December 31, 2017
(€bn)
Change vs.
December 31, 2016
€7.2bn
€8.1bn
€7.5bn
2014 2015 2016 2017
€7.1bn
€7.3bn
€8.2bn
€5.2bn
2014 2015 2016 2017 Mars
2018
High and Strong Cash-Flow Allows to Finance our
Acquisitions at Excellent Conditions
Free Cash Flow(1)
69
Net Debt
• Strong long-term credit ratings
• Moody’s A1; S&P AA
€14.1bn
(1) Free Cash Flow after change in working capital and after Capital Expenditures
(2) Including Animal Helath business
• Successful bond issues in March 2018
• €8bn; average cost of 0.96%
€6.7bn
March
2018
(2)
(2)
Strategically and Financially Compelling Acquisitions to
Enhance Sanofi’s Growth Profile and Create Value
70
Value
Value
Creation(1)
Build
Leadership
Position
Strengthen
Pipeline
Immediate
EPS
Accretion(2)
$11.6bn
€3.9bn    ~
   
(1) Bioverativ: projected to achieve ROIC in excess of cost of capital within three years
(2) Business EPS is a non-GAAP financial measure (see appendix to Sanofi quarterly financial release definitions)
Ablynx: including R&D expenses, the acquisition is expected to be neutral to 2018 and 2019 Business EPS
(3) Subject to completion of the acquisition
(3)
€1.5bn Capital Investments in 2017: Further Expansion in
Biologics Production Capacity
Capital Expenditure Evolution and Breakdown in 2017
71
€1.5bn€1.5bn
Pharma
Industrial
Affairs Pharma
R&D
Support Functions
Sanofi Pasteur
Pharma
Commercial
Operations
In 2018,
capital
expenditure
expected to reach
€1.7bn
€1.4bn
201720162015
11%
9%
7%
47%
26%
2017
Q1 2018: Performance of Specialty Care and Emerging Markets
Offsets U.S. Lantus® and Sevelamer Loss of Exclusivity
72
CER: Constant Exchange Rates; CER/CS: Constant Echange Rates and Constant Structure (adjusted for Bioverativ acquisition in Q1 2017)
(1) Q1 2018 net sales are down 1.1% at CER.CS
* After IFRS 15
Sales Business EPS
Q1 2018
€1.28
Q1 2017
€1.42
+1.4%
at CER
€7,898m
Q1 2018Q1 2017
€8,653m*
-0.4%
at CER(1)
Expected Return to Growth in H2 2018
73
Expected evolution of Business EPS in 2018: +2% to +5% at CER
(1,2)
(1) CER = Constant Exchange Rates
(2) Compared to FY2017 and barring major unforeseen adverse events. FY 2017 Business EPS of €5.52 after IFRS 15
• First quarter in line with 2018 guidance
• Impact of exchange rates movements
• Progress of new products
• Establishment of a leadership in rare blood disorders
• Strong long-term credit ratings confirmed
1
2
3
4
5
An Active Communication with our Individual Shareholders
Your publications
• Shareholder Handbook
• Letter to Shareholders
• Fact Sheet
Your online information
• www.sanofi.com/shareholders
• Sanofi IR mobile app
• Social Media
74
Twitter
YouTube
LinkedIn
Meetings with Shareholders
Meetings planned in 2018
• Salon Actionaria 2018
• November 22-23: Paris
75
Nantes
Paris
Bruxelles
Reims
Nancy
Lyon
Nice
Shareholders Committee
• 4 events planned in 2018
• Visit of Marcy-l’Etoile Sanofi Pasteur
industrial site
• Meetings with management and the
Chairman
PricewaterhouseCoopers Audit, ERNST & YOUNG et Autres
Reports by Statutory Auditors at the
Combined General Meeting
Reports and Statements Prepared by the Statutory Auditors
and Made Available to Shareholders
• Financial statements
• Statutory Auditors’ report on the statutory
financial statements (1st resolution)
• Statutory Auditors’ report on the consolidated
financial statements (2nd resolution)
• Related-party agreements and
commitments
• Statutory Auditors’ special report on related-party
agreements and commitments (4th resolution)
• Social, environmental and societal information
• Report by one of the Statutory Auditors, appointed
as an independent third party, on the consolidated
human resources, environmental and social
information included in the management report
77
• Profit forecasts
• Statutory Auditors’s report on forecasted
business net income per share
• Other statements
• Statutory Auditors’ statement on compensation
• Statutory Auditors’ statement on the
information provided in accordance with Article
L.225-115-5° of the French Commercial Code
with respect to the total amount of payments
made pursuant to paragraphs 1 and 4 of Article
238 bis of the French Tax Code
Questions & Answers
Vote on the Resolutions

Contenu connexe

Tendances

2015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 190520152015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 19052015Sanofi
 
2018/03 – IR Call – Odyssey Outcomes
2018/03 – IR Call – Odyssey Outcomes2018/03 – IR Call – Odyssey Outcomes
2018/03 – IR Call – Odyssey OutcomesSanofi
 
2015/03 - IR - Diabetes
2015/03 - IR - Diabetes2015/03 - IR - Diabetes
2015/03 - IR - DiabetesSanofi
 
Q4 and Full Year 2019 Results
Q4 and Full Year 2019 ResultsQ4 and Full Year 2019 Results
Q4 and Full Year 2019 ResultsSanofi
 
Q4 and FY 2017 Results
Q4 and FY 2017 ResultsQ4 and FY 2017 Results
Q4 and FY 2017 ResultsSanofi
 
2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC ConferenceSanofi
 
2019/12 – IR – Capital Markets Day
2019/12 – IR – Capital Markets Day2019/12 – IR – Capital Markets Day
2019/12 – IR – Capital Markets DaySanofi
 
Q2 2018 Results
Q2 2018 ResultsQ2 2018 Results
Q2 2018 ResultsSanofi
 
2015/07 – IR – Praluent
2015/07 – IR – Praluent2015/07 – IR – Praluent
2015/07 – IR – PraluentSanofi
 
Sanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial ResultsSanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial ResultsSanofi
 
General Meeting 2016
General Meeting 2016General Meeting 2016
General Meeting 2016Sanofi
 
2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HCSanofi
 
Q1 2017 Results by Sanofi
Q1 2017 Results by SanofiQ1 2017 Results by Sanofi
Q1 2017 Results by SanofiSanofi
 
2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC ConferenceSanofi
 
Annual Results 2014
Annual Results 2014Annual Results 2014
Annual Results 2014Sanofi
 
Q1 2018 Results
Q1 2018 ResultsQ1 2018 Results
Q1 2018 ResultsSanofi
 
Q3 2019 Results
Q3 2019 ResultsQ3 2019 Results
Q3 2019 ResultsSanofi
 
Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Sanofi
 
Q1 2020 Results
Q1 2020 ResultsQ1 2020 Results
Q1 2020 ResultsSanofi
 
2016/03 – Cowen HC Conference
2016/03 – Cowen HC Conference2016/03 – Cowen HC Conference
2016/03 – Cowen HC ConferenceSanofi
 

Tendances (20)

2015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 190520152015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 19052015
 
2018/03 – IR Call – Odyssey Outcomes
2018/03 – IR Call – Odyssey Outcomes2018/03 – IR Call – Odyssey Outcomes
2018/03 – IR Call – Odyssey Outcomes
 
2015/03 - IR - Diabetes
2015/03 - IR - Diabetes2015/03 - IR - Diabetes
2015/03 - IR - Diabetes
 
Q4 and Full Year 2019 Results
Q4 and Full Year 2019 ResultsQ4 and Full Year 2019 Results
Q4 and Full Year 2019 Results
 
Q4 and FY 2017 Results
Q4 and FY 2017 ResultsQ4 and FY 2017 Results
Q4 and FY 2017 Results
 
2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference
 
2019/12 – IR – Capital Markets Day
2019/12 – IR – Capital Markets Day2019/12 – IR – Capital Markets Day
2019/12 – IR – Capital Markets Day
 
Q2 2018 Results
Q2 2018 ResultsQ2 2018 Results
Q2 2018 Results
 
2015/07 – IR – Praluent
2015/07 – IR – Praluent2015/07 – IR – Praluent
2015/07 – IR – Praluent
 
Sanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial ResultsSanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial Results
 
General Meeting 2016
General Meeting 2016General Meeting 2016
General Meeting 2016
 
2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC
 
Q1 2017 Results by Sanofi
Q1 2017 Results by SanofiQ1 2017 Results by Sanofi
Q1 2017 Results by Sanofi
 
2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference
 
Annual Results 2014
Annual Results 2014Annual Results 2014
Annual Results 2014
 
Q1 2018 Results
Q1 2018 ResultsQ1 2018 Results
Q1 2018 Results
 
Q3 2019 Results
Q3 2019 ResultsQ3 2019 Results
Q3 2019 Results
 
Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Q4 and Full Year Results 2021
Q4 and Full Year Results 2021
 
Q1 2020 Results
Q1 2020 ResultsQ1 2020 Results
Q1 2020 Results
 
2016/03 – Cowen HC Conference
2016/03 – Cowen HC Conference2016/03 – Cowen HC Conference
2016/03 – Cowen HC Conference
 

Similaire à General Meeting 2018

General Meeting 2015
General Meeting 2015General Meeting 2015
General Meeting 2015Sanofi
 
amplats-afs-2015-final
amplats-afs-2015-finalamplats-afs-2015-final
amplats-afs-2015-finalGenevieve Mock
 
Institutional presentation 4 q172
Institutional presentation 4 q172Institutional presentation 4 q172
Institutional presentation 4 q172Kianne Paganini
 
2018 Scandinavian Life Science Reward and Governance Summary
2018 Scandinavian Life Science Reward and Governance Summary2018 Scandinavian Life Science Reward and Governance Summary
2018 Scandinavian Life Science Reward and Governance SummaryDeloitte UK
 
Institutional presentation 3 q17
Institutional presentation 3 q17Institutional presentation 3 q17
Institutional presentation 3 q17Kianne Paganini
 
ToTCOOP+i O3 o4 unit-8_final version_en
ToTCOOP+i O3 o4 unit-8_final version_enToTCOOP+i O3 o4 unit-8_final version_en
ToTCOOP+i O3 o4 unit-8_final version_enToTCOOPiTech
 
Institutional presentation 3 q17
Institutional presentation 3 q17Institutional presentation 3 q17
Institutional presentation 3 q17Kianne Paganini
 
financial statements and audit
financial statements and auditfinancial statements and audit
financial statements and auditسماج سيوك
 
Conflict Resolution Between Board And Executive Directors: Navig8 Management ...
Conflict Resolution Between Board And Executive Directors: Navig8 Management ...Conflict Resolution Between Board And Executive Directors: Navig8 Management ...
Conflict Resolution Between Board And Executive Directors: Navig8 Management ...Navig8 Management Consultancy
 
Financial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, NepalFinancial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, NepalLawrenceAkuboriCCO
 
Financial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, NepalFinancial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, NepalLawrenceAkuboriCCO
 
A combined solution to compliance and risk management for sustainability repo...
A combined solution to compliance and risk management for sustainability repo...A combined solution to compliance and risk management for sustainability repo...
A combined solution to compliance and risk management for sustainability repo...Ardea International
 
Q4 15 results presentation final
Q4 15 results presentation finalQ4 15 results presentation final
Q4 15 results presentation finalInvestorMarkit
 
1001205101
10012051011001205101
1001205101veriskir
 
Tintoria strategic plan 2 2019-2024
Tintoria strategic plan 2 2019-2024Tintoria strategic plan 2 2019-2024
Tintoria strategic plan 2 2019-2024Fred Mmbololo
 
Investment Policy for Insurers - June 2012
 Investment Policy for Insurers - June 2012 Investment Policy for Insurers - June 2012
Investment Policy for Insurers - June 2012Strategic Asset Alliance
 
Top Priorities For Finance in 2016
Top Priorities For Finance in 2016Top Priorities For Finance in 2016
Top Priorities For Finance in 2016Eric Gerster
 

Similaire à General Meeting 2018 (20)

General Meeting 2015
General Meeting 2015General Meeting 2015
General Meeting 2015
 
amplats-afs-2015-final
amplats-afs-2015-finalamplats-afs-2015-final
amplats-afs-2015-final
 
Institutional presentation 4 q172
Institutional presentation 4 q172Institutional presentation 4 q172
Institutional presentation 4 q172
 
Sadudeen CV_updated 2 (2)
Sadudeen CV_updated 2 (2)Sadudeen CV_updated 2 (2)
Sadudeen CV_updated 2 (2)
 
2018 Scandinavian Life Science Reward and Governance Summary
2018 Scandinavian Life Science Reward and Governance Summary2018 Scandinavian Life Science Reward and Governance Summary
2018 Scandinavian Life Science Reward and Governance Summary
 
Institutional presentation 3 q17
Institutional presentation 3 q17Institutional presentation 3 q17
Institutional presentation 3 q17
 
ToTCOOP+i O3 o4 unit-8_final version_en
ToTCOOP+i O3 o4 unit-8_final version_enToTCOOP+i O3 o4 unit-8_final version_en
ToTCOOP+i O3 o4 unit-8_final version_en
 
Institutional presentation 3 q17
Institutional presentation 3 q17Institutional presentation 3 q17
Institutional presentation 3 q17
 
financial statements and audit
financial statements and auditfinancial statements and audit
financial statements and audit
 
Conflict Resolution Between Board And Executive Directors: Navig8 Management ...
Conflict Resolution Between Board And Executive Directors: Navig8 Management ...Conflict Resolution Between Board And Executive Directors: Navig8 Management ...
Conflict Resolution Between Board And Executive Directors: Navig8 Management ...
 
Unit 5 ED.pptx
Unit 5 ED.pptxUnit 5 ED.pptx
Unit 5 ED.pptx
 
Financial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, NepalFinancial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, Nepal
 
Financial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, NepalFinancial Management Training at Global Learning Event, Kathmandu, Nepal
Financial Management Training at Global Learning Event, Kathmandu, Nepal
 
A combined solution to compliance and risk management for sustainability repo...
A combined solution to compliance and risk management for sustainability repo...A combined solution to compliance and risk management for sustainability repo...
A combined solution to compliance and risk management for sustainability repo...
 
ICSA Guernsey Conference 2019 - Updated presentation slides
ICSA Guernsey Conference 2019 - Updated presentation slidesICSA Guernsey Conference 2019 - Updated presentation slides
ICSA Guernsey Conference 2019 - Updated presentation slides
 
Q4 15 results presentation final
Q4 15 results presentation finalQ4 15 results presentation final
Q4 15 results presentation final
 
1001205101
10012051011001205101
1001205101
 
Tintoria strategic plan 2 2019-2024
Tintoria strategic plan 2 2019-2024Tintoria strategic plan 2 2019-2024
Tintoria strategic plan 2 2019-2024
 
Investment Policy for Insurers - June 2012
 Investment Policy for Insurers - June 2012 Investment Policy for Insurers - June 2012
Investment Policy for Insurers - June 2012
 
Top Priorities For Finance in 2016
Top Priorities For Finance in 2016Top Priorities For Finance in 2016
Top Priorities For Finance in 2016
 

Plus de Sanofi

Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsFourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsSanofi
 
Third quarter 2023 Results
Third quarter 2023 ResultsThird quarter 2023 Results
Third quarter 2023 ResultsSanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023Sanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlightsSanofi
 
First quarter 2023 results
First quarter 2023 resultsFirst quarter 2023 results
First quarter 2023 resultsSanofi
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlightsSanofi
 
Sanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi
 
2022 full-year results highlights
2022 full-year results highlights2022 full-year results highlights
2022 full-year results highlightsSanofi
 
L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 Sanofi
 
Presentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsPresentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsSanofi
 
Q3 2022 Results
Q3 2022 ResultsQ3 2022 Results
Q3 2022 ResultsSanofi
 
Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Sanofi
 
Second quarter 2022 results
Second quarter 2022 results Second quarter 2022 results
Second quarter 2022 results Sanofi
 
Q1 First quarter results
Q1 First quarter resultsQ1 First quarter results
Q1 First quarter resultsSanofi
 
Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Sanofi
 
First quarter 2022 results
First quarter 2022 resultsFirst quarter 2022 results
First quarter 2022 resultsSanofi
 
Presentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovationPresentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovationSanofi
 

Plus de Sanofi (20)

Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsFourth quarter and full year 2023 results
Fourth quarter and full year 2023 results
 
Third quarter 2023 Results
Third quarter 2023 ResultsThird quarter 2023 Results
Third quarter 2023 Results
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlights
 
First quarter 2023 results
First quarter 2023 resultsFirst quarter 2023 results
First quarter 2023 results
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlights
 
Sanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 results
 
2022 full-year results highlights
2022 full-year results highlights2022 full-year results highlights
2022 full-year results highlights
 
L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022
 
Presentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsPresentation of the Q3 2022 Results
Presentation of the Q3 2022 Results
 
Q3 2022 Results
Q3 2022 ResultsQ3 2022 Results
Q3 2022 Results
 
Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022
 
Second quarter 2022 results
Second quarter 2022 results Second quarter 2022 results
Second quarter 2022 results
 
Q1 First quarter results
Q1 First quarter resultsQ1 First quarter results
Q1 First quarter results
 
Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Résultats du premier trimestre 2022
Résultats du premier trimestre 2022
 
First quarter 2022 results
First quarter 2022 resultsFirst quarter 2022 results
First quarter 2022 results
 
Presentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovationPresentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovation
 

Dernier

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)Mohamed Rizk Khodair
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 

Dernier (20)

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 

General Meeting 2018

  • 2. Serge Weinberg Chairman of the Board of Directors Introduction
  • 3. Forward Looking Statements 3 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • 4. Agenda 4 2017 Financial Performance Jérôme Contamine, Executive Vice-President, Chief Financial Officer Introduction & Governance Serge Weinberg, Chairman of the Board of Directors Compensation Policy Patrick Kron, Chairman of the Compensation Committee Progress in Research & Development Elias Zerhouni, President, Global R&D Strategic Outlook Olivier Brandicourt, Chief Executive Officer Reports by Statutory Auditors at the Combined General Meeting PricewaterhouseCoopers Audit ERNST & YOUNG et Autres Questions & Answers Vote on the Resolutions
  • 5. Serge Weinberg Chairman of the Board of Directors Governance
  • 6. An Independent, Experienced and Diversified Board of Directors 6 (1) Numbers not taking into account directors representing employees, pursuant to the recommendations of the AFEP-MEDEF Corporate Governance Code (2) Percentage not taking into account directors representing employees, pursuant to the relevant regulation • Board of Directors composed of 16 directors • Widely independent (11 out of 14(1)) and gender sensitive (43%(2)) • International (6 non-French directors, i.e. 38%) • 2 directors representing employees • Further implementation of roadmap with a controlled and progressive renewal • More scientific and pharmaceutical expertise • Development of competences in the digital area • Preservation of key competences • Restricted number of directorships allowing an enhanced participation and dedication Renewal of the terms of: • Olivier Brandicourt • Christian Mulliez • Patrick Kron Appointment of: • Emmanuel Babeau
  • 7. A Dedicated and Active Board of Directors In 2017 • A sustained level of activity: 9 meetings • Activities related to: • financial statements and financial matters • compensation matters • appointment and governance matters • Review of significant proposed alliances, acquisitions and strategic opportunities • Review of key businesses • Evaluation of the activities of the Board and its Committees • 3 executive sessions 7 High directors’ attendance rate > 95 %
  • 8. Four Specialized Committees 1. Audit Committee • Chaired by Robert Castaigne(1) • 3 financial experts • 3 independent members out of 4 • 7 meetings in 2017 • Review of the annual, half-year and quarterly financial results • Review of the main risks that may affect the results • Review of the draft financial resolutions • Update on the implementation of IFRS 15 and IFRS 9 accounting standards 8 1 1. Compensation Committee • Chaired by Patrick Kron • 3 independent members out of 4 • 3 meetings in 2017 • Review of the fixed and variable compensation of the CEO, the Chairman of the Board, and the members of the Executive Committee • Determination of the amount of directors’ attendance fees • Update on changes in « say on pay » requirements • Launch of a new employee share-ownership plan 2 Attendance rate: 93% Attendance rate: 100% (1) Following this General Meeting, the Audit Committee will be chaired by Fabienne Lecorvaisier
  • 9. Four Specialized Committees (cont’d) 1. Appointments and Governance Committee • Chaired by Serge Weinberg • 3 independent members out of 3 • 3 meetings in 2017 • Succession planning • Follow-up of the discussions held with main shareholders and proxy advisors on governance matters • Evaluation of the activities of the Board and its Committees • Changes in the Board’s composition 9 3 1. Strategic Committee • Chaired by Serge Weinberg • 2 independent members out of 4 • 10 meetings in 2017 • Review of external growth opportunities • Review of the strategy • Global environment • Research and development • Long range financials 4 Attendance rate: 100% Attendance rate: 100%
  • 10. A Fifth Specialized Committee in 2018 1. Scientific Committee • Decision of the Board of Directors on March 6, 2018, upon recommendation of the Appointments and Governance Committee • Scientific Committee in charge of assisting the Board on the strategic orientations in the field of R&D • Thomas Südhof appointed Chairman of the Committee 10 5 Creation in 2018
  • 11. Sanofi Share Performance vs. Pharma Company Peers since January 2018 11 Stock Performance in local currencies Source: Bloomberg, April 27, 2018 Local currencies: € for SAN & Bayer; US $ for LLY, PFE, MRCK, ABBV, BMY, JnJ, AZ & Novartis; DKK for Novo; CHF for Roche; £ for GSK 10.8% 5.7% 2.2%2.1% -0.7% -2.1% -5.6% -7.3%-7.9%-8.2%-9.3% -11.3% -13.6% -14.7% ADR
  • 12. Dividend: A Crucial Element of the Return to Shareholders • 2017 dividend proposed by the Board of Directors: €3.03 per share(1) • 24th consecutive year of dividend increase 12(1) Submitted to the vote of this General Meeting Evolution of Dividend €2.20 €2.40 €2.50 €2.65 €2.77 €2.80 €2.85 €2.93 €2.96 €3.03 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
  • 13. An International and Diversified Shareholder Base 13Source: NASDAQ Corporate Solutions, December 31, 2017 United States France Institutional Investors 76.7% UK Other EU countries Asia Germany Switzerland Canada Rest of the world L’Oréal Individual Shareholders Employees Miscellaneous 1,254,019,904 shares 1.5% 9.4% 5.9% 6.5% 1.6% 14.5% 29.1% 2.2% 3.3% 1.6% 3.3% 6.6% 14.6% 7.4%
  • 14. Strenghten Employee Share Ownership Sanofi wants to strenghen its employee share ownership • 22nd resolution voted by the AGM of May 10, 2017 • For an implementation in June 2018 • In more than 70 countries 14 3 initiatives since 2013 Action 2013 Action 2016 Action 2017 >1.6 million shares subscribed >1.7 million shares subscribed >1.5 million shares subscribed
  • 15. Patrick Kron Chairman of the Compensation Committee Compensation Policy
  • 16. Compensation Policy for the Chairman of the Board 16 • Stable annual fixed gross compensation • No attendance fees • No annual variable compensation • No equity compensation • No compensation payable upon termination of office • No pension entitlement • No exceptional compensation
  • 17. Compensation Elements of Serge Weinberg in 2017 17 Amounts Comments Fixed compensation €700,000 Fixed compensation unchanged since his appointment on May 17, 2010 €8,353 Company car Total €708,353
  • 18. Compensation Policy for the Chief Executive Officer 18 • Annual fixed compensation • Annual variable compensation • Equity compensation • Options to subscribe for shares • Performance shares • No Director’s attendance fees • No exceptional compensation • Compensation on leaving office • Termination benefit • Top-up pension benefit subject to fulfillment of a performance condition (voluntary implementation of the Macron law as of January 2017) • Non-compete undertaking
  • 19. Compensation Elements of Olivier Brandicourt in 2017 19 (1) In accordance with article L. 225-100 of the French commercial code, payment of annual variable compensation in respect of the year ended on December 31, 2017 is contingent on favorable vote at this General Meeting Amounts Comments Fixed compensation €1,200,000 Same compensation since his appointment in 2015 Variable compensation €1,792,800(1) From 0% to 250% of the target fixed compensation to 150% of the fixed compensation Achieved rate: 149.4% of fixed compensation Options 220,000 options to subscribe for shares Exercise price: €88.97 Performance shares 50,000 performance shares Benefits in kind €318 Social benefit in relation to social contribution payment made by Sanofi on CEO’s behalf
  • 20. Variable Compensation of Olivier Brandicourt in 2017 20 • 40% based on financial indicators • 60% based on specific individual objectives • External growth (14%) • Excellence of product launches (10%) • Operational transformation (12%) • Organization and staff relations (12%) • New product pipeline (12%) • Quantitative criteria account for 76% of the overall annual gross variable compensation objectives Attainment 99.6% of the 150% target, i.e. 149.4% of the fixed compensation
  • 21. Equity Compensation of Olivier Brandicourt in 2017 21 • Performance conditions measured over 3 years • 3 performance criteria • Business Net Income (50%) • Return On Assets or ROA (30%) • Total Shareholder Return or TSR (20%) • 220,000 options to subscribe for shares • 50,000 performance shares 2017 Grant Plan Conditions 2015 Plan • Allocation rate of 81.12% • Definitive acquisition in June 2019 • Performance conditions measured over 3 years (2015-2017) • 3 performance criteria • Business Net Income (50%) – 102.2% • Return On Assets or ROA (30%) – 100% • Total Shareholder Return or TSR (20%) – 0% Plan Conditions
  • 22. Olivier Brandicourt Chief Executive Officer Strategic Outlook
  • 23. Sanofi, a Health Journey Partner 23
  • 25. For 3 Years: Strategic Transformation for Better Healthcare and Continued Value Creation 25 An unprecedented effort in Research & Development 1 2 3 4 Impact of digital opportunities A new operational model Refocusing on our strenghs
  • 26. A Robust R&D Pipeline in 6 Therapeutic Areas • €5.5bn invested in R&D in 2017 • 15.6% of company sales • 74 projects in development • Immunology • Multiple Sclerosis & Neurology • Oncology • Rare Diseases & Rare Blood Disorders • Diabetes & Cardiovascular • Vaccines 26 3737 Studies for additional indications NMEs & Vaccines in developement 28Molecules & vaccines in late stage development 1 An unprecedented effort in Research & Development
  • 27. Dupixent® Launched in Atopic Dermatitis A Product with Multiple Potential Indications • Moderate-to-Severe Atopic Dermatitis • Strong launch in the U.S. • Ongoing or planned launches in 20 countries in the coming months • Moderate-to-Severe Asthma • Regulatory submissions in the U.S. and Europe • Significant commercial potential in multiple diseases(1) • Nasal Polyposis, Eosinophilic Esophagitis, Chronic Obstructive Pulmonary Disease, Allergies… 27(1) If approved in indications by relevant Health Authority 1 An unprecedented effort in Research & Development Pictures of a patient from a Phase 3 clinical trial before and after treatment with dupilumab. Results may vary 2017 Sales: €219m
  • 28. Two Promising Products in Oncology 28 cemiplimab isatuximab • PD-1 inhibitor monoclonal antibody • Being evaluated by European and U.S. health authorities in Cutaneous Squamous Cell Carcinoma • Phase 3 studies ongoing in other cancers Cemiplimab is partenered with Regeneron Cemiplimab and isatuximab are currently investigational agents and have not been evaluated by any regulatory authority • Anti-CD38 monoclonal antibody • Pivotal studies in Multiple Myeloma (bone marrow cancer) ongoing; submission planned in 2018 1 An unprecedented effort in Research & Development
  • 29. Praluent® Significantly Reduces Risk of Cardiovascular Events in High-Risk Patients 29 Praluent® (alirocumab) is developed in collaboration with Regeneron For more information: consult the press release from March 10, 2018 (1) HR=0.85, IC : 0.78-0.93, p=0.0003 (2) HR=0.85; IC: 0.73-0.98, nominal p value = 0.026 Approved in more than 60 countries Focus on patients with the greatest health risk Praluent® significantly reduced the risk of major adverse cardiovascular events(1) Associated with a reduction in all-cause mortality(2) A more pronounced effect observed in patients with baseline LDL-C levels ≥ 100 mg/dL    1 An unprecedented effort in Research & Development
  • 30. For 3 Years: Strategic Transformation for Better Healthcare and Continued Value Creation 30 An unprecedented effort in Research & Development 1 2 3 4 Impact of digital opportunities A new operational model Refocusing on our strenghs
  • 31. Consolidating our Leadership in Rare Diseases 31 2 Refocusing on our strengths Restructuring of the alliance with Alnylam • Global rights obtained on fitusiran, currently in Phase 3 in hemophilia 1 Building a center of expertise in rare blood disorders Three complementary moves
  • 32. Bioverativ: a Leading Hemophilia Portfolio, a New Platform in Other Rare Blood Disorders 32 U.S. biotechnology company • 2017 Revenues: $1,168m, +31.7% Leadership position in the large hemophilia market • Two marketed products R&D programs • Cold agglutinin disease, hemophilia and other rare blood disorders (1) (2) (1) Treatment of Hemophilia A (2) Treatment of Hemophilia B 2 Refocusing on our strenghs 2
  • 33. Belgian biotechnology company • An innovative Nanobody® platform which strengthens Sanofi’s multi-targeting R&D strategy Ablynx: Provides a Leading Technology Platform and Strengthens R&D Pipeline(1) 33 Expanding rare blood disorders franchise(2) • Caplacizumab: submitted in Europe for the treatment of Acquired Thrombotic Thrombocytopenic Purpura Complementary R&D programs • Hematology, inflammatory diseases, immuno-oncology, respiratory diseases (1) Subject to the completion of the acquisition (2) Linked to Bioverativ’s acquisition 2 Refocusing on our strenghs 3
  • 34. Flu Vaccines: Protein Sciences Broadens our Portfolio with Flublok® 34 65 year old 50 year old 6 month old Change standard of care Age-related product differentiation Flublok(1) Fluzone HD QIVFluzone HD TIV Better efficacy Fluzone QIV VaxiGrip QIV Fluzone TIV VaxiGrip TIV HD= High-Dose; TIV= trivalent; QIV= quadrivalent (1) The only FDA approved recombinant protein-based influenza vaccine approved for all adults 18 and older Better efficacy 2 Refocusing on our strenghs
  • 35. For 3 Years: Strategic Transformation for Better Healthcare and Continued Value Creation 35 An unprecedented effort in Research & Development 1 2 3 4 Impact of digital opportunities A new operational model Refocusing on our strenghs
  • 36. An Organization Based on Five Global Business Units (GBUs) 36 Sanofi Genzyme Specialty Care Sanofi Pasteur Vaccines Diabetes & Cardiovascular Consumer Healthcare General Medicines & Emerging Markets 5 GBUs 3 A new operational model
  • 37. For 3 Years: Strategic Transformation for Better Healthcare and Continued Value Creation 37 An unprecedented effort in Research & Development 1 2 3 4 Impact of digital opportunities A new operational model Refocusing on our strenghs
  • 38. Digitalization Offers Enormous Potential 38 4 • Accelerating research • Better diabetes management, beyond medicines • Better interaction with patients, physicians and payers • Digitalization of the industrial tool Impact of digital opportunities
  • 39. A diversified and strong model based on three categories of activity 39 High scientific content Strong added value Diabetes and cardiovascular disease Predictable and profitable growth 1 2 3
  • 40. Sanofi Genzyme – Specialty Care Success of the New Immunology Franchise Immunology • Successful launch of Dupixent® • Kevzara® launch progressing well Multiple Sclerosis • Strong, growing franchise Rare Diseases • Bioverativ acquisition and Ablynx planned acquisition strenghten leadership position(1) Oncology • Significant expansion of development pipeline 40 Global Specialty Care Franchise Sales €6,678m 19% of company sales +14.5% at CER Immunology Multiple Sclerosis Rare Diseases Oncology 2017 CER = Constant Exchange Rates (1) Subject to the completion of the Ablynx acquisition
  • 41. Sanofi Pasteur – Vaccines A Global Leader in a Growing Market 41 Global Vaccines Franchise Sales €5,101m 14.6% of company sales Pediatric Combinations Influenza Vaccines Meningitis/Pneumo Adult Boosters Travel/Endemic Other +14.5% at CER 2017 Leading vaccines in 5 areas: • Influenza • Pediatric Combinations • Meningitis • Adult Boosters • Travelers and other vaccines for endemic countries A strenghtened product portfolio with the acquisition of Protein Sciences CER = Constant Exchange Rates
  • 42. Diabetes and Cardiovascular Diseases 42 Diabetes Franchise • Global sales down 11.1% at CER in 2017 • Decrease in U.S. sales partly offset by performance in Emerging Markets • Success of Toujeo® in 2017: sales up 27% to €816m Cardiovascular Franchise • Praluent®: positive results of ODYSSEY OUTCOMES Global DCV Franchise Sales €6,905m 19.7% of company sales United States Europe Emerging Markets Rest of the World -20.2% +0.1% +11.6% -0.6% 2017 All growth rates are expressed at Constant Exchange Rates (CER)
  • 43. Sanofi is One of the Top 3 Players in Consumer Healthcare(1) 43 Integration of Boehringher Ingelheim CHC business completed Global CHC Franchise Sales €4,832m 13.8% of company sales +46.3% at CER Allergies, Cough & Cold Pain Nutritionals Digestive Other 2017 CER = Constant Exchange Rates (1) Source: Nicholas Hall & Company FY 2017
  • 44. General Medicines & Emerging Markets: Leading Position in Emerging Countries Due to an Adapted Product Portfolio 44 (1) World excluding U.S., Canada, Europe, Japan, South Korea, Australia, New Zealand and Puerto Rico (2) Market share (without Vaccines), IMS MIDAS | FY 2017 (3) At Constant Exchange Rates and Constant Structure Established Products • Account for nearly one third of company sales Emerging Markets(1) • Sanofi ranks #1(2) • 2017 sales: €10,258m, +6.0%(3) • Supported by strong sales growth in China: €2.2bn, +15.1%(3) 2017 GEM Business Unit Sales €14,048m 40% of company sales
  • 45. Progress in Protecting the Environment • Water saving • Objective: reduce water consumption between 2010 and 2020 by 25 % • Carbon footprint • Objective: reduce greenhouse gas emissions by 50 % in 2025 45 - 22% water consumption at the end of 2017 - 23% greenhouse gas emissions since 2010
  • 46. Access to Healthcare for Those Most in Need in Emerging Countries • Commitment against infectious diseases • Malaria: >450 million treatments provided in 10 years • Tuberculosis • Poliomyelitis: world leader in polio vaccine • Fight against tropical neglected diseases • Sleeping sickness • In 15 years: reduction from 30,000 to 2,000 cases • Fexinidazole, developed with DNDi, would be the first all-oral treatment Polio Number of cases down 99% in 30 years DNDi (Drugs for Neglected Diseases initiative): a not-for-profit research and development organization working to deliver new treatments for neglected diseases 46
  • 47. Take Action for Disadvantaged Children and Educate them About Health • Sanofi Espoir Foundation – My Child Matters • For 12 years, enabling children with cancer in low-income countries to benefit from better care • Kids • Preventing diabetes in children at school and encourage healthy lifestyles • Program launched in Brazil, the United Arab Emirates, Egypt, Japan, India, Pakistan and Poland 55 projects in 42 countries Actions in 175 schools, >60,000 children 47
  • 48. In France: Promoting Access to Healthcare for Those in Need • Women in vulnerable situations • Pregnancy monitoring at the Maison des femmes de St Denis • Those who live on the street • Partnerships with: Samu social, Croix Rouge Française, Emmaüs, Médecins du Monde • Migrants • A new program prepared by Sanofi Espoir Foundation 48
  • 49. Elias Zerhouni Président, Global R&D Progress in R&D
  • 50. Key Achievements in R&D in 2017 50 (1) In collaboration with Regeneron (2) In collaboration with Hanmi (3) In collaboration with Lexicon Pivotal study starts Regulatory submissions Product approvals • Dupixent®(1) in Atopic Dermatitis in adult patients • Kevzara®(1) in Rheumatoid Arthritis • Suliqua® in Diabetes (Europe) • Dupixent®(1) in Asthma in adult patients (U.S.) • VaxiGrip® QIV IM in 6-35 month-olds (EU) • Dupixent®(1) in Asthma in patients aged 6-11 year-old • Dupixent®(1) in Atopic Dermatitis in patients 6-11 years-old, 12-17 years-old, 6 month-5 years-old • Dupilumab(1) in Nasal Polyposis • Efpeglenatide(2) in type 2 Diabetes • Sotagliflozin(3) in combination therapies in type 2 Diabetes • Isatuximab in Multiple Myeloma and other cancers • Cemiplimab(1) in Non-small Cell Lung Cancer, Basal Cell Carcinoma and Cervical Cancer • Fluzone ® QIV HD
  • 51. Key R&D Milestones in 2018 51 Q1 Q2 Q3 Q4 Potential submissions Cemiplimab(1) in Cutaneous Squamous Cell Carcinoma  Sotagliflozin(2) in Type 1 Diabetes  Dupilumab(1) in Asthma in adolescents/adults (EU)  Praluent®(1) ODYSSEY OUTCOMES label update Dupilumab(1) in Atopic Dermatitis in adolescents Isatuximab in Multiple Myeloma in combination with PomDex (U.S.) Expected pivotal trial read-outs Praluent(1) ODYSSEY OUTCOMES  Cemiplimab(1) in Basal Cell Carcinoma Dupilumab(1) in Nasal Polyps Expected start of pivotal studies Mavacamten(3) in Obstructive Hypertrophic Cardiomyopathy Fitusiran in Hemophilia A & B as prophylactic treatment  Isatuximab in 1st line Multiple Myeloma in Stem Cell Transplant eligible patients Venglustat in Autosomal Dominant Polycystic Kidney Disease Sotagliflozin(2) in Worsening Heart Failure in Diabetes patients Dupilumab(1) in Eosinophilic Esophagitis Dupilumab(1) in Chronic Obstructive Pulmonary Disease Alemtuzumab in Primary Progressive Multiple Sclerosis (1) In collaboration with Regeneron (2) In collaboration with Lexicon (3) In collaboration with Myokardia
  • 52. New R&D Model Based on Three Strategical Transformations 52 Mode of action biologicsTherapeutic Modalities small molecules mono-targeting Technology Platforms licensing proprietary multi-targeting
  • 53. Sanofi Focuses on Leading Technology Platforms Addressing Multiple Disease Targets with Single Complex Molecules siRNA Conjugates BioNTech mRNA Mixture PRR Antibody Conjugates Trigonal Peptides 53 Multispecific Antibodies (bi- & tri-specific) Ablynx Nanobodies PRR: Pattern Recognition Receptor CH2 CH3 VHHVHH Acquisition of Ablynx internalizes platform for Nanobodies®, a novel class of next-generation biologics
  • 54. Build New Foundations for Growth 54 Multiple Sclerosis Cardiovascular Immunology Oncology Hematology 2011 2012 2013 2014 2015 2016 2017 2018 2019 Diabetes
  • 55. Dupilumab – A Pipeline in a Product Being Developed in Multiple Indications 55 dupilumab Atopic Dermatitis Asthma Nasal Polyposis Eosinophilic Esophagitis • Breakthrough therapy in moderate-to-severe AD • First-in-class biologic treatment • Efficacy in 3 pivotal trials • Largest Phase 3 program of a biologic therapy in asthma • Positive Proof of Concept data • No currently approved biologic • Phase 3 expected to start in Q4 2018 • Positive Proof of Concept data • No currently approved biologic • Phase 3 fully enrolled Dupilumab is developed in collaboration with Regeneron
  • 56. ODYSSEY OUTCOMES Provides Strong Clinical Evidence of Patient Benefit from Long-Term Therapy with Praluent®(1) 56 Praluent® is developed in collaboration with Regeneron ACS = acute coronary syndrome; LDL-C = low-density lipoprotein cholesterol (1) In addition to maximally tolerated statin therapy (2) HR= 0.85, CI: 0.78-0.93, p=0.0003 (3) HR= 0.85; CI: 0.73-0.98; nominal p value = 0.026 (4) HR= 0.76, CI: 0.65-0.87 et HR=0.71, CI: 0.56-0.90 respectively Long-term trial ~19,000 patients Patient Impact • Greatest clinical benefit shown in high risk post-ACS patients • In highest risk patients with LDL-C ≥100mg/dL, Praluent® was associated with a 24% reduction of major adverse cardiovascular events and 29% reduction in all-cause death(4) Positive Results • Significant reduction in major adverse cardiac events of 15%(2) • Associated with 15% reduction in all-cause mortality(3) • Safety profile consistent with previous findings
  • 57. Screening Cemiplimab: Promising Results in Treatment of Cutaneous Squamous Cell Carcinoma • One of the most common cancers globally with significant unmet needs • 200K to 400K new cases/year in the U.S.(1) • Severe morbidity and mortality with recurrence • ~3,900 – 8,800 deaths/year in the U.S.(1) • Pivotal studies in other indications • Non-Small Cell Lung Cancer • Basal Cell Carcinoma • Cervical Cancer 57 Results after 6 weeks treatment with cemiplimab Cutaneous Squamous Cell Carcinoma - Results from Phase 2 Pivotal Study (1) Karia PS and al. J Am Acad Dermatol. 2013;68:957–66
  • 58. Isatuximab: a Significant Opportunity in Large and Growing Multiple Myeloma Market • Worldwide Multiple Myeloma market expected to reach $29bn in 2022(1) • Double/triple branded combination use • New options with prolonged progression free survival benefit • Globally ~114k new cases diagnosed annually • Anti-CD38 class rapidly becoming standard of care • Combinability without increased toxicity • Unprecedented progression free survival prolongation • Proof of concept studies to evaluate combination use of isatuximab in 9 other cancers 58 $14bn $29bn 2017 2022e Anti-CD38 IMiDs PI’s Other Isatuximab is an investigational agent and has not been evaluated by any regulatory authority IMiD= immunomodulatory agent; PI= proteasome inhibitor (1) EvaluatePharma® October 2017
  • 59. A continuous innovation flow(1) 59 fitusiran(7) siRNA inhibitor Hemophilia A/B - U.S./EU 2022 and beyond2018 2019 2020 (1) Excluding Phase 1 - Data related to all studies published on clinicaltrials.gov (2) Also known as SAR439684 and REGN2810 (3) Also known as SAR231893 (4) Submission strategy for the U.S. under evaluation (5) Submission for the U.S. expected in 2020 (6) Acid Sphingomyelinase Deficiency (7) Following the Alnylam/Sanofi strategic restructuring of the RNAi therapeutics rare disease alliance announced in January 2018, Sanofi now has global rights on fitusiran (8) Currently operating as separate entities. Reported dates are based on prior Bioverativ disclosure of study completion date (9) Gaucher Related Parkinson’s Disease (10)Also known as MEDI8897 (**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products NewmolecularentitiesAdditionalIndications Dupixent®(**) Anti-IL4Rα mAb AD 6 months - 5 years old U.S./EU Tuberculosis Recombinant subunit vaccine GZ389988 TRKA antagonist Osteoarthritis - U.S./EU SAR425899 GLP-1/GCG dual agonist Obesity/Overweight in T2D U.S./EU isatuximab anti-CD38 mAb 3L RRMM (ICARIA) - U.S. cemiplimab(2)(**) PD-1 inhibitor mAb Advanced CSCC - U.S./EU HIV Viral vector prime & rgp120 boost vaccine SAR156597 IL4/IL13 bi-specific mAb Systemic Scleroderma - U.S./EU efpeglenatide(**) Long acting GLP1-R agonist Type 2 Diabetes - U.S./EU cemiplimab(2)(**) PD-1 inhibitor mAb 1L NSCLC - U.S./EU cemiplimab(2)(**) PD-1 inhibitor mAb 2L Cervical Cancer - U.S./EU Men Quad TT Adv. generation meningococcal U.S. & EU – 10 Yrs + SP0232 mAbs(10)(**) Respiratory syncytial virus U.S. SAR422459 ABCA4 gene therapy Stargardt Disease -- U.S./EU avalglucosidase alfa Neo GAA Pompe Disease - U.S./EU SAR407899 rho kinase Microvascular Angina - U.S./EU dupilumab(3)(**) Anti-IL4Ra mAb Nasal Polyposis Adult - U.S./EU sarilumab(**) Anti-IL6R mAb Polyarticular Juvenile Idiopathic Arthritis - U.S./EU Dupixent®(3)(**) Anti-IL4Ra mAb AD 12 – 17 years old - U.S./EU Rabies VRVg Purified vero rabies vaccine venglustat Oral GCS inhibitor Fabry Disease - U.S./EU cemiplimab(2)(**) PD-1 inhibitor mAb Advanced BCC - U.S./EU Praluent®(**) Anti-PCSK9 mAb CV events reduction - U.S./EU Shan 6 DTP-HepB-Polio-Hib Pediatric hexavalent vaccine dupilumab(3)(**) Anti-IL4Rα mAb Asthma 6 - 11 years old U.S./EU venglustat Oral GCS inhibitor Gaucher Disease Type 3 U.S./EU Dupixent®(3)(**) Anti-IL4Ra mAb AD 6 - 11 years old - U.S./EU dupilumab(3)(**) Anti-IL4Ra mAb Eosinophilic Esophagitis U.S./EU Fluzone® QIV HD Quadrivalent inactivated Influenza vaccine - High dose dupilumab(3)(**) Anti-IL4Ra mAb Asthma adults & adolesc. - EU Adacel+ Tdap booster sotagliflozin(**)n Oral SGLT-1&2 inhibitor Type 2 Diabetes – EU(5) olipudase alfa rhASM ASD(6) - U.S./EU sotagliflozin(**)n Oral SGLT-1&2 inhibitor Type 1 Diabetes - U.S./EU Combination ferroquine / OZ439(**) Antimalarial - U.S./EU venglustat Oral GCS inhibitor GrPD(9) - U.S./EU Aubagio® teriflunomide Relapsing MS – Ped. - U.S./EU sarilumab(**) Anti-IL6R mAb Systemic Juvenile Arthritis U.S./EU SAR341402 Rapid acting insulin Type 1/2 Diabetes - EU(4) Pediatric pentavalent vaccine DTP-Polio-Hib (Japan) isatuximab Anti-CD38 mAb (IMROZ) 1L Newly Diagnosed MM U.S./EU isatuximab Anti-CD38 mAb 1-3L RRMM (IKEMA) - U.S./EU 2021 sotagliflozin(**) SGLT 1/2 inhibitor Worsening Heart Failure in Diabetes - U.S./EU Infectious DiseasesRare Diseases Immuno-inflammation Diabetes MS, Neuro, Gene therapy Vaccines Oncology Cardiovascular & metabolism Rare Blood Disorders SAR440340(**) Anti-IL33 mAb Asthma - U.S./EU BIVV009(8) Anti Complement C1s mAb Cold Agglutinin Disease SAR566658 Maytansin-loaded anti-CA6 mAb Triple Negative Breast Cancer
  • 60. Jérôme Contamine Executive Vice-President, Chief Financial Officer 2017 Financial Performance
  • 61. 2017 Business EPS in-Line with Expectations Sales 61 CER = Constant Exchange Rates CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others Business EPS 2017 €35,055m 2016 €33,821m +0.5% at CER/CS €5.68 20172016 €5.54 -0.4% at CER/CS
  • 62. 2017: A Year of Transition Supported by Solid Growth Drivers 62 Growth at CER% of Sales Growth at CER/CS CER = Constant Exchange Rates CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others 19.1% 14.6% 19.7% Specialty Medicines Vaccines Diabetes & Cardiovascular €6,678M €5,101M €6,905M €1,778M +14.5% +14.5% -9.6% 71.6% Pharmaceuticals €25,122M 5.1% 27.7% Established Rx Products Others €9,761M -3.4% -3.3% +14.6% +8.3% -9.6% -3.8% -3.1% 13.8% Consumer Healthcare €4,832M +46.3% +2.1% -1.2% -1.3%
  • 63. 33.8% 27.2% 29.3%9.7% A Balanced Geographic Breakdown of Sales 63 United States €11,855m -3.5% Europe(1) €9,525m +0.7% Emerging Markets(2) €10,258m +6.0% Rest of World(3) €3,417m -1.5% All growth at CER (constant exchange rates) / CS (constant structure), adjusted for BI CHC business, termination of SPMSD and others (1) Western Europe & Eastern Europe (excluding Eurasia) (2) World excluding U.S., Canada, Europe, Japan, South Korea, Australia, New Zealand and Puerto Rico (3) Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico Strong sales growth in China: €2,2bn, +15.1%
  • 64. Sanofi Met 2017 Financial Performance Objectives 64 FY 2017 ResultsObjectives Gross margin 70.6%70-71% at CER OpEx growth rate at CER +2.0% At similar rate as in 2016(1) Tax rate 23.5%24-25% Business EPS guidance at CER -0.4%Broadly stable Dividend growth +2.4%Progressive      CER = Constant Exchange Rates (1) OpEx growth rate of 2.5% at CER in 2016
  • 65. Business Operating Income Up 3% at CER in 2017 65 €m 2017 2016 %Change (reported €) % Change (CER) % Change (CER/CS) Sales 35,055 33,821 +3.6% +5.6% +0.5% Other revenues 1,149 887 +29.5% +32.9% +36.6% Gross profit 24,759 24,006 +3.1% +5.3% +0.4% R&D expenses (5,472) (5,172) +5.8% +7.0% +5.0% SG&A expenses (10,058) (9,486) +6.0% +7.8% +0.4% Business operating income 9,343 9,285 +0.6% +3.0% -1.1% Effective tax rate 23.5% 23.3% - - - Business net income excluding Animal Health 6,964 6,832 +1.9% +4.2% - Business net income of Animal Health - 476 -100.0% -100.0% - Business net income 6,964 7,308 -4.7% -2.6% CER = Constant Exchange Rates CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others
  • 66. Continued Investment in R&D and Strict Cost Management Gross Margin 66 R&D Expenses SG&A Expenses 201720162017201620172016 15.6% of sales 28.7% of sales €10,058m €5,472m €5,172m €9,486m 28.0% of sales 15.3% of sales 70.6% 71.0% +5.0% +0.4% All growth rates at CER = Constant Exchange Rates / CS = Constant Structure, adjusted for BI CHC business, termination of SPMSD and others
  • 67. Net Income Benefited From Gain on the Disposal of the Animal Health Business 67(1) In 2016: other elements SPMSD: €52m, Impairment loss on Alnylam investment: €457m €m 2017 2016 % Change (reported €) Business net income 6,964 7,308 (4.7%) Amortization of intangible assets (1,866) (1,692) Impairment of intangible assets (293) (192) Fair value remeasurement of contingent consideration liabilities (159) (135) Expenses arising from the impact of acquisitions on inventories (166) - Restructuring costs and similar items (731) (879) Other gains and losses, and litigation (215) 211 Tax effect of items listed above 1,126 841 Other tax items (742) (113) Associates and non-controlling interests (127) 31 Animal Health items 4,643 (162) Others(1) - (509) Net income attributable to equity holders of Sanofi 8,434 4,709 79.1%
  • 68. Strong Balance Sheet on December 31, 2017 68 ASSETS LIABILITIES & EQUITY Net Debt (A-B) Intangible assets Other non-current assets WCR(1) Net cash (B) Equity attributable Provisions and other non-current liabilities Financial debt (A)(2) 58.3 11.8 (1) Working Capital Requirement (2) Including interest rate and currency derivatives used to hedge debt 5.2 +2.2 -0.3 +0.2 +0.0 +0.6 -0.7 -3.0 53.4 20.1 1.8 10.3 15.5 -3.0 December 31, 2017 (€bn) Change vs. December 31, 2016
  • 69. €7.2bn €8.1bn €7.5bn 2014 2015 2016 2017 €7.1bn €7.3bn €8.2bn €5.2bn 2014 2015 2016 2017 Mars 2018 High and Strong Cash-Flow Allows to Finance our Acquisitions at Excellent Conditions Free Cash Flow(1) 69 Net Debt • Strong long-term credit ratings • Moody’s A1; S&P AA €14.1bn (1) Free Cash Flow after change in working capital and after Capital Expenditures (2) Including Animal Helath business • Successful bond issues in March 2018 • €8bn; average cost of 0.96% €6.7bn March 2018 (2) (2)
  • 70. Strategically and Financially Compelling Acquisitions to Enhance Sanofi’s Growth Profile and Create Value 70 Value Value Creation(1) Build Leadership Position Strengthen Pipeline Immediate EPS Accretion(2) $11.6bn €3.9bn    ~     (1) Bioverativ: projected to achieve ROIC in excess of cost of capital within three years (2) Business EPS is a non-GAAP financial measure (see appendix to Sanofi quarterly financial release definitions) Ablynx: including R&D expenses, the acquisition is expected to be neutral to 2018 and 2019 Business EPS (3) Subject to completion of the acquisition (3)
  • 71. €1.5bn Capital Investments in 2017: Further Expansion in Biologics Production Capacity Capital Expenditure Evolution and Breakdown in 2017 71 €1.5bn€1.5bn Pharma Industrial Affairs Pharma R&D Support Functions Sanofi Pasteur Pharma Commercial Operations In 2018, capital expenditure expected to reach €1.7bn €1.4bn 201720162015 11% 9% 7% 47% 26% 2017
  • 72. Q1 2018: Performance of Specialty Care and Emerging Markets Offsets U.S. Lantus® and Sevelamer Loss of Exclusivity 72 CER: Constant Exchange Rates; CER/CS: Constant Echange Rates and Constant Structure (adjusted for Bioverativ acquisition in Q1 2017) (1) Q1 2018 net sales are down 1.1% at CER.CS * After IFRS 15 Sales Business EPS Q1 2018 €1.28 Q1 2017 €1.42 +1.4% at CER €7,898m Q1 2018Q1 2017 €8,653m* -0.4% at CER(1)
  • 73. Expected Return to Growth in H2 2018 73 Expected evolution of Business EPS in 2018: +2% to +5% at CER (1,2) (1) CER = Constant Exchange Rates (2) Compared to FY2017 and barring major unforeseen adverse events. FY 2017 Business EPS of €5.52 after IFRS 15 • First quarter in line with 2018 guidance • Impact of exchange rates movements • Progress of new products • Establishment of a leadership in rare blood disorders • Strong long-term credit ratings confirmed 1 2 3 4 5
  • 74. An Active Communication with our Individual Shareholders Your publications • Shareholder Handbook • Letter to Shareholders • Fact Sheet Your online information • www.sanofi.com/shareholders • Sanofi IR mobile app • Social Media 74 Twitter YouTube LinkedIn
  • 75. Meetings with Shareholders Meetings planned in 2018 • Salon Actionaria 2018 • November 22-23: Paris 75 Nantes Paris Bruxelles Reims Nancy Lyon Nice Shareholders Committee • 4 events planned in 2018 • Visit of Marcy-l’Etoile Sanofi Pasteur industrial site • Meetings with management and the Chairman
  • 76. PricewaterhouseCoopers Audit, ERNST & YOUNG et Autres Reports by Statutory Auditors at the Combined General Meeting
  • 77. Reports and Statements Prepared by the Statutory Auditors and Made Available to Shareholders • Financial statements • Statutory Auditors’ report on the statutory financial statements (1st resolution) • Statutory Auditors’ report on the consolidated financial statements (2nd resolution) • Related-party agreements and commitments • Statutory Auditors’ special report on related-party agreements and commitments (4th resolution) • Social, environmental and societal information • Report by one of the Statutory Auditors, appointed as an independent third party, on the consolidated human resources, environmental and social information included in the management report 77 • Profit forecasts • Statutory Auditors’s report on forecasted business net income per share • Other statements • Statutory Auditors’ statement on compensation • Statutory Auditors’ statement on the information provided in accordance with Article L.225-115-5° of the French Commercial Code with respect to the total amount of payments made pursuant to paragraphs 1 and 4 of Article 238 bis of the French Tax Code
  • 79. Vote on the Resolutions